

FINANCIAL TEAR SHEET

CORPORATE PROFILE

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias.


We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

STOCK INFORMATION

IRTC (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$70.25
Change (%)	▼ 0.93 (1.31%)
Volume	197,118
52 Week Low	\$33.72
Market Cap	\$1,679,857,680
Rolling EPS	-1.53
PE Ratio	0
Shares Outstanding	23,600,136

Data as of 05/24/18 4:00 p.m. ET



RECENT NEWS

Date	Title
05/16/18	JAMA Cardiology publishes RHYTHM Study Revealing Link Between Total AF Burden and Stroke Risk
05/16/18	JAMA Cardiology publishes RHYTHM Study Revealing Link Between Total AF Burden and Stroke Risk
05/02/18	iRhythm Technologies Announces First Quarter Financial Results

UPCOMING EVENTS

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
05/24/18	8-K
05/21/18	4
05/10/18	10-Q
05/09/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed.